nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—PNLIP—exocrine gland—cervical cancer	0.0455	0.0749	CbGeAlD
Orlistat—FASN—Irinotecan—Topotecan—cervical cancer	0.0298	1	CbGdCrCtD
Orlistat—DAGLB—decidua—cervical cancer	0.0263	0.0433	CbGeAlD
Orlistat—PLA2G7—decidua—cervical cancer	0.0213	0.035	CbGeAlD
Orlistat—ABHD16A—uterine cervix—cervical cancer	0.0209	0.0345	CbGeAlD
Orlistat—PLA2G7—endometrium—cervical cancer	0.0202	0.0332	CbGeAlD
Orlistat—ABHD16A—decidua—cervical cancer	0.0199	0.0328	CbGeAlD
Orlistat—ABHD12—uterine cervix—cervical cancer	0.0196	0.0323	CbGeAlD
Orlistat—PLA2G7—mammalian vulva—cervical cancer	0.0195	0.0321	CbGeAlD
Orlistat—ABHD16A—endometrium—cervical cancer	0.0189	0.0312	CbGeAlD
Orlistat—DAGLB—female gonad—cervical cancer	0.0188	0.031	CbGeAlD
Orlistat—ABHD12—decidua—cervical cancer	0.0187	0.0308	CbGeAlD
Orlistat—ABHD16A—mammalian vulva—cervical cancer	0.0183	0.0302	CbGeAlD
Orlistat—ABHD12—endometrium—cervical cancer	0.0177	0.0292	CbGeAlD
Orlistat—ABHD12—mammalian vulva—cervical cancer	0.0172	0.0283	CbGeAlD
Orlistat—FASN—uterine cervix—cervical cancer	0.0165	0.0271	CbGeAlD
Orlistat—FASN—decidua—cervical cancer	0.0157	0.0258	CbGeAlD
Orlistat—PLA2G7—female gonad—cervical cancer	0.0152	0.025	CbGeAlD
Orlistat—PLA2G7—vagina—cervical cancer	0.0151	0.0249	CbGeAlD
Orlistat—PNLIP—female reproductive system—cervical cancer	0.0147	0.0242	CbGeAlD
Orlistat—Bullous eruption—Topotecan—cervical cancer	0.0145	0.11	CcSEcCtD
Orlistat—FASN—mammalian vulva—cervical cancer	0.0144	0.0237	CbGeAlD
Orlistat—ABHD16A—female gonad—cervical cancer	0.0143	0.0235	CbGeAlD
Orlistat—ABHD16A—vagina—cervical cancer	0.0142	0.0234	CbGeAlD
Orlistat—FASN—uterus—cervical cancer	0.0137	0.0226	CbGeAlD
Orlistat—PNLIP—female gonad—cervical cancer	0.0134	0.022	CbGeAlD
Orlistat—ABHD12—female gonad—cervical cancer	0.0134	0.022	CbGeAlD
Orlistat—ABHD12—vagina—cervical cancer	0.0133	0.0219	CbGeAlD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—GP6—cervical cancer	0.0124	0.0539	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—GP6—cervical cancer	0.0124	0.0539	CbGpPWpGaD
Orlistat—FASN—SREBP signalling—YY1—cervical cancer	0.0122	0.0531	CbGpPWpGaD
Orlistat—DAGLB—lymph node—cervical cancer	0.0121	0.0199	CbGeAlD
Orlistat—FASN—female gonad—cervical cancer	0.0112	0.0185	CbGeAlD
Orlistat—FASN—vagina—cervical cancer	0.0112	0.0184	CbGeAlD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—GP5—cervical cancer	0.0108	0.0471	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—GP5—cervical cancer	0.0108	0.0471	CbGpPWpGaD
Orlistat—PLA2G7—lymph node—cervical cancer	0.00978	0.0161	CbGeAlD
Orlistat—ABHD16A—lymph node—cervical cancer	0.00917	0.0151	CbGeAlD
Orlistat—ABHD12—lymph node—cervical cancer	0.0086	0.0142	CbGeAlD
Orlistat—PLA2G4A—uterine cervix—cervical cancer	0.00791	0.013	CbGeAlD
Orlistat—FASN—SREBF and miR33 in cholesterol and lipid homeostasis—MTOR—cervical cancer	0.00758	0.0329	CbGpPWpGaD
Orlistat—PLA2G4A—decidua—cervical cancer	0.00754	0.0124	CbGeAlD
Orlistat—PLA2G4A—renal system—cervical cancer	0.0074	0.0122	CbGeAlD
Orlistat—FASN—lymph node—cervical cancer	0.00721	0.0119	CbGeAlD
Orlistat—PLA2G4A—endometrium—cervical cancer	0.00716	0.0118	CbGeAlD
Orlistat—PLA2G4A—mammalian vulva—cervical cancer	0.00692	0.0114	CbGeAlD
Orlistat—DAGLA—Hemostasis—GP6—cervical cancer	0.00639	0.0278	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—SERPIND1—cervical cancer	0.00639	0.0278	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—SERPIND1—cervical cancer	0.00639	0.0278	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—GP6—cervical cancer	0.00639	0.0278	CbGpPWpGaD
Orlistat—Dysmenorrhoea—Topotecan—cervical cancer	0.00632	0.0476	CcSEcCtD
Orlistat—DAGLA—N-cadherin signaling events—CTNNB1—cervical cancer	0.00599	0.026	CbGpPWpGaD
Orlistat—DAGLB—N-cadherin signaling events—CTNNB1—cervical cancer	0.00599	0.026	CbGpPWpGaD
Orlistat—PLA2G4A—female reproductive system—cervical cancer	0.00593	0.00976	CbGeAlD
Orlistat—FASN—Validated transcriptional targets of deltaNp63 isoforms—HES1—cervical cancer	0.00566	0.0246	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—GP5—cervical cancer	0.00559	0.0243	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—GP5—cervical cancer	0.00559	0.0243	CbGpPWpGaD
Orlistat—PLA2G4A—female gonad—cervical cancer	0.00539	0.00888	CbGeAlD
Orlistat—PLA2G4A—vagina—cervical cancer	0.00536	0.00883	CbGeAlD
Orlistat—Neoplasm—Topotecan—cervical cancer	0.0052	0.0392	CcSEcCtD
Orlistat—Dermatitis bullous—Topotecan—cervical cancer	0.00437	0.0329	CcSEcCtD
Orlistat—FASN—Validated transcriptional targets of deltaNp63 isoforms—NOTCH1—cervical cancer	0.00427	0.0186	CbGpPWpGaD
Orlistat—PLA2G7—Peptide hormone metabolism—CTNNB1—cervical cancer	0.00398	0.0173	CbGpPWpGaD
Orlistat—Cramp muscle—Topotecan—cervical cancer	0.00376	0.0283	CcSEcCtD
Orlistat—PLA2G4A—lymph node—cervical cancer	0.00347	0.00571	CbGeAlD
Orlistat—Infestation—Topotecan—cervical cancer	0.00322	0.0242	CcSEcCtD
Orlistat—Infestation NOS—Topotecan—cervical cancer	0.00322	0.0242	CcSEcCtD
Orlistat—Neuropathy peripheral—Topotecan—cervical cancer	0.00315	0.0238	CcSEcCtD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—GP6—cervical cancer	0.00312	0.0136	CbGpPWpGaD
Orlistat—Hepatobiliary disease—Topotecan—cervical cancer	0.00304	0.0229	CcSEcCtD
Orlistat—FASN—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—cervical cancer	0.00304	0.0132	CbGpPWpGaD
Orlistat—Haemoglobin—Topotecan—cervical cancer	0.0029	0.0219	CcSEcCtD
Orlistat—Haemorrhage—Topotecan—cervical cancer	0.00289	0.0218	CcSEcCtD
Orlistat—Pharyngitis—Topotecan—cervical cancer	0.00287	0.0216	CcSEcCtD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—GP5—cervical cancer	0.00273	0.0119	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—TAAR6—cervical cancer	0.00268	0.0116	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—TAAR6—cervical cancer	0.00268	0.0116	CbGpPWpGaD
Orlistat—Immune system disorder—Topotecan—cervical cancer	0.00261	0.0197	CcSEcCtD
Orlistat—Mediastinal disorder—Topotecan—cervical cancer	0.0026	0.0196	CcSEcCtD
Orlistat—Alopecia—Topotecan—cervical cancer	0.00255	0.0192	CcSEcCtD
Orlistat—Malnutrition—Topotecan—cervical cancer	0.00251	0.0189	CcSEcCtD
Orlistat—CYP3A4—renal system—cervical cancer	0.00244	0.00402	CbGeAlD
Orlistat—Back pain—Topotecan—cervical cancer	0.00243	0.0183	CcSEcCtD
Orlistat—DAGLA—Signaling by GPCR—TAAR6—cervical cancer	0.00243	0.0106	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—TAAR6—cervical cancer	0.00243	0.0106	CbGpPWpGaD
Orlistat—Muscle spasms—Topotecan—cervical cancer	0.00242	0.0182	CcSEcCtD
Orlistat—FASN—AMPK Signaling—MTOR—cervical cancer	0.00235	0.0102	CbGpPWpGaD
Orlistat—FASN—SREBP signalling—MTOR—cervical cancer	0.00235	0.0102	CbGpPWpGaD
Orlistat—Ill-defined disorder—Topotecan—cervical cancer	0.00233	0.0176	CcSEcCtD
Orlistat—Angioedema—Topotecan—cervical cancer	0.0023	0.0173	CcSEcCtD
Orlistat—Malaise—Topotecan—cervical cancer	0.00227	0.0171	CcSEcCtD
Orlistat—Cough—Topotecan—cervical cancer	0.00219	0.0165	CcSEcCtD
Orlistat—Chest pain—Topotecan—cervical cancer	0.00214	0.0161	CcSEcCtD
Orlistat—Myalgia—Topotecan—cervical cancer	0.00214	0.0161	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.00213	0.016	CcSEcCtD
Orlistat—Discomfort—Topotecan—cervical cancer	0.00211	0.0159	CcSEcCtD
Orlistat—Anaphylactic shock—Topotecan—cervical cancer	0.00205	0.0155	CcSEcCtD
Orlistat—Infection—Topotecan—cervical cancer	0.00204	0.0154	CcSEcCtD
Orlistat—Nervous system disorder—Topotecan—cervical cancer	0.00201	0.0152	CcSEcCtD
Orlistat—Skin disorder—Topotecan—cervical cancer	0.00199	0.015	CcSEcCtD
Orlistat—Hyperhidrosis—Topotecan—cervical cancer	0.00198	0.0149	CcSEcCtD
Orlistat—CYP3A4—female reproductive system—cervical cancer	0.00196	0.00322	CbGeAlD
Orlistat—DAGLB—Signaling by GPCR—WNT2—cervical cancer	0.0019	0.00824	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—WNT2—cervical cancer	0.0019	0.00824	CbGpPWpGaD
Orlistat—Musculoskeletal discomfort—Topotecan—cervical cancer	0.00187	0.0141	CcSEcCtD
Orlistat—Paraesthesia—Topotecan—cervical cancer	0.00184	0.0139	CcSEcCtD
Orlistat—DAGLB—GPCR downstream signaling—AKAP13—cervical cancer	0.00183	0.00797	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—AKAP13—cervical cancer	0.00183	0.00797	CbGpPWpGaD
Orlistat—Dyspepsia—Topotecan—cervical cancer	0.00181	0.0136	CcSEcCtD
Orlistat—Decreased appetite—Topotecan—cervical cancer	0.00178	0.0134	CcSEcCtD
Orlistat—Gastrointestinal disorder—Topotecan—cervical cancer	0.00177	0.0133	CcSEcCtD
Orlistat—Fatigue—Topotecan—cervical cancer	0.00177	0.0133	CcSEcCtD
Orlistat—Pain—Topotecan—cervical cancer	0.00175	0.0132	CcSEcCtD
Orlistat—Feeling abnormal—Topotecan—cervical cancer	0.00169	0.0127	CcSEcCtD
Orlistat—Gastrointestinal pain—Topotecan—cervical cancer	0.00168	0.0126	CcSEcCtD
Orlistat—DAGLA—Signaling by GPCR—AKAP13—cervical cancer	0.00167	0.00724	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—AKAP13—cervical cancer	0.00167	0.00724	CbGpPWpGaD
Orlistat—Urticaria—Topotecan—cervical cancer	0.00163	0.0123	CcSEcCtD
Orlistat—Body temperature increased—Topotecan—cervical cancer	0.00162	0.0122	CcSEcCtD
Orlistat—Abdominal pain—Topotecan—cervical cancer	0.00162	0.0122	CcSEcCtD
Orlistat—PLA2G4A—Hemostasis—SERPIND1—cervical cancer	0.00161	0.00699	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—GP6—cervical cancer	0.00161	0.00699	CbGpPWpGaD
Orlistat—Hypersensitivity—Topotecan—cervical cancer	0.00151	0.0114	CcSEcCtD
Orlistat—Asthenia—Topotecan—cervical cancer	0.00147	0.0111	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	0.00146	0.00633	CbGpPWpGaD
Orlistat—Pruritus—Topotecan—cervical cancer	0.00145	0.0109	CcSEcCtD
Orlistat—DAGLB—Signaling by GPCR—WNT5A—cervical cancer	0.00144	0.00625	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—WNT5A—cervical cancer	0.00144	0.00625	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TAAR6—cervical cancer	0.00144	0.00624	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TAAR6—cervical cancer	0.00144	0.00624	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—GP5—cervical cancer	0.00141	0.00611	CbGpPWpGaD
Orlistat—Diarrhoea—Topotecan—cervical cancer	0.0014	0.0106	CcSEcCtD
Orlistat—FASN—AMPK Signaling—TP53—cervical cancer	0.00139	0.00603	CbGpPWpGaD
Orlistat—Dizziness—Topotecan—cervical cancer	0.00136	0.0102	CcSEcCtD
Orlistat—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.00136	0.00589	CbGpPWpGaD
Orlistat—PNLIP—Disease—WNT2—cervical cancer	0.00133	0.00576	CbGpPWpGaD
Orlistat—CYP3A4—Tryptophan metabolism—UBE3A—cervical cancer	0.00131	0.00568	CbGpPWpGaD
Orlistat—Vomiting—Topotecan—cervical cancer	0.0013	0.00983	CcSEcCtD
Orlistat—Rash—Topotecan—cervical cancer	0.00129	0.00975	CcSEcCtD
Orlistat—Dermatitis—Topotecan—cervical cancer	0.00129	0.00974	CcSEcCtD
Orlistat—Headache—Topotecan—cervical cancer	0.00129	0.00968	CcSEcCtD
Orlistat—PLA2G4A—AGE/RAGE pathway—CASP8—cervical cancer	0.00127	0.00553	CbGpPWpGaD
Orlistat—PLA2G4A—PDGF Pathway—STAT3—cervical cancer	0.00123	0.00535	CbGpPWpGaD
Orlistat—Nausea—Topotecan—cervical cancer	0.00122	0.00918	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—TAAR6—cervical cancer	0.00119	0.00517	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	0.00114	0.00494	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	0.00114	0.00494	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—WNT2—cervical cancer	0.00112	0.00487	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—WNT2—cervical cancer	0.00112	0.00487	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—CA9—cervical cancer	0.00105	0.00456	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—cervical cancer	0.00103	0.00446	CbGpPWpGaD
Orlistat—PNLIP—Disease—WNT5A—cervical cancer	0.00101	0.00437	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—AKAP13—cervical cancer	0.000984	0.00428	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—AKAP13—cervical cancer	0.000984	0.00428	CbGpPWpGaD
Orlistat—PLA2G4A—AGE/RAGE pathway—CASP3—cervical cancer	0.000963	0.00418	CbGpPWpGaD
Orlistat—FASN—Disease—WNT2—cervical cancer	0.000939	0.00408	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—WNT2—cervical cancer	0.000929	0.00404	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—WNT5A—cervical cancer	0.00085	0.00369	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—WNT5A—cervical cancer	0.00085	0.00369	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—AKAP13—cervical cancer	0.000816	0.00354	CbGpPWpGaD
Orlistat—PLA2G4A—AGE/RAGE pathway—STAT3—cervical cancer	0.000809	0.00352	CbGpPWpGaD
Orlistat—PLA2G7—Metabolism of proteins—CTNNB1—cervical cancer	0.000751	0.00326	CbGpPWpGaD
Orlistat—FASN—Metabolism—CA9—cervical cancer	0.000742	0.00322	CbGpPWpGaD
Orlistat—PLA2G4A—AGE/RAGE pathway—EGFR—cervical cancer	0.000735	0.00319	CbGpPWpGaD
Orlistat—FASN—Disease—WNT5A—cervical cancer	0.000711	0.00309	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—WNT5A—cervical cancer	0.000704	0.00306	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—TAAR6—cervical cancer	0.000612	0.00266	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—NOTCH2—cervical cancer	0.000596	0.00259	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—NOTCH2—cervical cancer	0.000596	0.00259	CbGpPWpGaD
Orlistat—PNLIP—Disease—HES1—cervical cancer	0.000579	0.00251	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	0.000544	0.00236	CbGpPWpGaD
Orlistat—PNLIP—Disease—MTHFR—cervical cancer	0.000508	0.00221	CbGpPWpGaD
Orlistat—PNLIP—Disease—TERT—cervical cancer	0.000507	0.0022	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—NOTCH2—cervical cancer	0.000494	0.00215	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—HES1—cervical cancer	0.000489	0.00212	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—HES1—cervical cancer	0.000489	0.00212	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—STAT3—cervical cancer	0.000485	0.00211	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—TP53—cervical cancer	0.000481	0.00209	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—TP53—cervical cancer	0.000481	0.00209	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—WNT2—cervical cancer	0.000477	0.00207	CbGpPWpGaD
Orlistat—PNLIP—Disease—FGFR3—cervical cancer	0.000465	0.00202	CbGpPWpGaD
Orlistat—PNLIP—Disease—NOTCH1—cervical cancer	0.000437	0.0019	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TERT—cervical cancer	0.000428	0.00186	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TERT—cervical cancer	0.000428	0.00186	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—MTHFR—cervical cancer	0.000426	0.00185	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AKAP13—cervical cancer	0.000419	0.00182	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	0.000412	0.00179	CbGpPWpGaD
Orlistat—FASN—Disease—HES1—cervical cancer	0.000409	0.00178	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—HES1—cervical cancer	0.000405	0.00176	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	0.000397	0.00172	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—FGFR3—cervical cancer	0.000393	0.00171	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—FGFR3—cervical cancer	0.000393	0.00171	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—NOTCH1—cervical cancer	0.000369	0.0016	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—NOTCH1—cervical cancer	0.000369	0.0016	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—WNT5A—cervical cancer	0.000362	0.00157	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TAAR6—cervical cancer	0.000361	0.00157	CbGpPWpGaD
Orlistat—FASN—Disease—MTHFR—cervical cancer	0.00036	0.00156	CbGpPWpGaD
Orlistat—FASN—Disease—TERT—cervical cancer	0.000359	0.00156	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TERT—cervical cancer	0.000355	0.00154	CbGpPWpGaD
Orlistat—FASN—Disease—FGFR3—cervical cancer	0.000329	0.00143	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—EGFR—cervical cancer	0.000329	0.00143	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—EGFR—cervical cancer	0.000329	0.00143	CbGpPWpGaD
Orlistat—PNLIP—Disease—MTOR—cervical cancer	0.000327	0.00142	CbGpPWpGaD
Orlistat—PNLIP—Disease—CD4—cervical cancer	0.000327	0.00142	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—FGFR3—cervical cancer	0.000326	0.00142	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CA9—cervical cancer	0.000319	0.00138	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	0.000314	0.00137	CbGpPWpGaD
Orlistat—FASN—Disease—NOTCH1—cervical cancer	0.000309	0.00134	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—NOTCH1—cervical cancer	0.000306	0.00133	CbGpPWpGaD
Orlistat—FASN—Metabolism—MTHFR—cervical cancer	0.000301	0.00131	CbGpPWpGaD
Orlistat—PNLIP—Disease—CTNNB1—cervical cancer	0.00029	0.00126	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—WNT2—cervical cancer	0.000282	0.00123	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MTOR—cervical cancer	0.000277	0.0012	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MTOR—cervical cancer	0.000277	0.0012	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	0.000264	0.00115	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CASP3—cervical cancer	0.000254	0.00111	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CASP3—cervical cancer	0.000254	0.00111	CbGpPWpGaD
Orlistat—PNLIP—Disease—STAT3—cervical cancer	0.000253	0.0011	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKAP13—cervical cancer	0.000248	0.00108	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CTNNB1—cervical cancer	0.000245	0.00107	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CTNNB1—cervical cancer	0.000245	0.00107	CbGpPWpGaD
Orlistat—FASN—Disease—MTOR—cervical cancer	0.000232	0.00101	CbGpPWpGaD
Orlistat—FASN—Disease—CD4—cervical cancer	0.000231	0.001	CbGpPWpGaD
Orlistat—PNLIP—Disease—EGFR—cervical cancer	0.00023	0.000999	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MTOR—cervical cancer	0.000229	0.000996	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—WNT5A—cervical cancer	0.000214	0.000929	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—STAT3—cervical cancer	0.000214	0.000929	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—STAT3—cervical cancer	0.000214	0.000929	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CASP3—cervical cancer	0.000211	0.000916	CbGpPWpGaD
Orlistat—FASN—Disease—CTNNB1—cervical cancer	0.000205	0.000892	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CTNNB1—cervical cancer	0.000203	0.000883	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—EGFR—cervical cancer	0.000194	0.000844	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—EGFR—cervical cancer	0.000194	0.000844	CbGpPWpGaD
Orlistat—FASN—Disease—STAT3—cervical cancer	0.000179	0.000777	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—STAT3—cervical cancer	0.000177	0.000769	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TP53—cervical cancer	0.000163	0.000709	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TP53—cervical cancer	0.000163	0.000709	CbGpPWpGaD
Orlistat—FASN—Disease—EGFR—cervical cancer	0.000163	0.000707	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—EGFR—cervical cancer	0.000161	0.000699	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NOTCH2—cervical cancer	0.00015	0.000652	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TP53—cervical cancer	0.000135	0.000587	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—MTHFR—cervical cancer	0.000129	0.000562	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HES1—cervical cancer	0.000123	0.000534	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TP53—cervical cancer	0.000121	0.000526	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TERT—cervical cancer	0.000108	0.000468	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FGFR3—cervical cancer	9.89e-05	0.00043	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NOTCH1—cervical cancer	9.29e-05	0.000403	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—EGFR—cervical cancer	8.27e-05	0.000359	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CA9—cervical cancer	7.46e-05	0.000324	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MTOR—cervical cancer	6.96e-05	0.000302	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CASP3—cervical cancer	6.4e-05	0.000278	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CTNNB1—cervical cancer	6.17e-05	0.000268	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—STAT3—cervical cancer	5.38e-05	0.000234	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EGFR—cervical cancer	4.89e-05	0.000212	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TP53—cervical cancer	4.1e-05	0.000178	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—MTHFR—cervical cancer	3.03e-05	0.000132	CbGpPWpGaD
